- Previous Close
45.68 - Open
46.05 - Bid 46.02 x 800
- Ask 46.05 x 800
- Day's Range
45.61 - 46.06 - 52 Week Range
34.74 - 47.44 - Volume
426,050 - Avg. Volume
1,240,004 - Market Cap (intraday)
10.228B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
131.49 - EPS (TTM)
0.35 - Earnings Date Jul 31, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 30, 2024
- 1y Target Est
50.59
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, such as STR assays for human ID, and assays for food contamination; PCR instruments include digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It also offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a collaboration with the U.S. FBI; and with Bio-Manguinhos/Fiocruz to detect malaria and dengue. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
www.qiagen.com5,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: QGEN
View More
Performance Overview: QGEN
Trailing total returns as of 9/19/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QGEN
View MoreValuation Measures
Market Cap
10.15B
Enterprise Value
10.66B
Trailing P/E
132.11
Forward P/E
19.80
PEG Ratio (5yr expected)
1.24
Price/Sales (ttm)
5.18
Price/Book (mrq)
2.98
Enterprise Value/Revenue
5.50
Enterprise Value/EBITDA
30.12
Financial Highlights
Profitability and Income Statement
Profit Margin
3.75%
Return on Assets (ttm)
1.74%
Return on Equity (ttm)
2.07%
Revenue (ttm)
1.94B
Net Income Avi to Common (ttm)
72.69M
Diluted EPS (ttm)
0.35
Balance Sheet and Cash Flow
Total Cash (mrq)
890.24M
Total Debt/Equity (mrq)
42.85%
Levered Free Cash Flow (ttm)
233M
Research Analysis: QGEN
View MoreCompany Insights: QGEN
QGEN does not have Company Insights
Research Reports: QGEN
View MoreQiagen Earnings: Small Increases on 2024 Outlook Following Solid Operating Results
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
RatingPrice TargetQiagen Still Pushing for Higher Growth Than Its End Markets
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
RatingPrice TargetQiagen Earnings: No Fair Value Estimate Change as Reset Period Continues About as Expected
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
RatingPrice TargetQiagen Earnings: Management Guides to Weak 2024 That Mildly Affects Our Fair Value Estimate
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
RatingPrice Target